KEAP1 and lung adenocarcinoma: In this regard, the group of Heymach took advantage of isogenic pairs of murine and human KRAS-driven lung adenocarcinoma cells (K tumors) with concomitant knockdown of LKB1 (KL tumors) and KEAP1 (KLK tumors) to explore the potential metabolic adaptations that might be targeted.